Inadequate Risk Information Primary Cause of DDMAC Warnings, Abrams Says

Drug Industry Daily
KEYWORDS Advertising / FDA

Pharmaceutical firms should design drug promotions in a way that gives equal weight to a product’s risks and claims, suggests the head of the FDA’s advertising oversight division, which has ratcheted up its scrutiny of drug promotions in recent months.

To View This Article:


Subscribe To Drug Industry Daily